Journal
IMMUNOTHERAPY
Volume 7, Issue 3, Pages 229-241Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.14.120
Keywords
cancer; chimeric antigen receptor; ErbB receptors; HER2; immunotherapy; T cells
Categories
Funding
- Breast Cancer Campaign
- Worldwide Cancer Research
- Leukaemia and Lymphoma Research
- Pancreatic Cancer UK
- Wellcome Trust
- Jon Moulton Charitable Foundation
- Experimental Cancer Medicine Center at King's College London
- National Institute for Health Research (NIHR) Biomedical Research Center based at Guy's and St Thomas' NHS Foundation Trust
- King's College London
- Pancreatic Cancer UK [2013 RIF - Maher] Funding Source: researchfish
- Worldwide Cancer Research [13-1017] Funding Source: researchfish
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) based immunotherapy has been under development for the last 25 years and is now a promising new treatment modality in the field of cancer immunotherapy. The approach involves genetically engineering T cells to target malignant cells through expression of a bespoke fusion receptor that couples an HLA-independent antigen recognition domain to one or more intracellular T-cell activating modules. Multiple clinical trials are now underway in several centers to investigate CAR T-cell immunotherapy of diverse hematologic and solid tumor types. The most successful results have been achieved in the treatment of patients with B-cell malignancies, in whom several complete and durable responses have been achieved. This review focuses on the preclinical and clinical development of CAR T-cell immunotherapy of solid cancers, targeted against members of the ErbB family.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available